Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) FCF Margin: 2014-2020

Historic FCF Margin for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to 2,983.06%.

  • Larimar Therapeutics' FCF Margin rose 48666.00% to 2,983.06% in Q1 2020 from the same period last year, while for Mar 2020 it was 1,230.31%, marking a year-over-year decrease of 138881.00%. This contributed to the annual value of 1,290.03% for FY2019, which is 142835.00% down from last year.
  • As of Q1 2020, Larimar Therapeutics' FCF Margin stood at 2,983.06%, which was up 35.64% from 2,199.17% recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' FCF Margin registered a high of 123,287.50% during Q4 2017, and its lowest value of -728.87% during Q2 2019.
  • Its 3-year average for FCF Margin is 2,135.19%, with a median of 2,496.40% in 2019.
  • Per our database at Business Quant, Larimar Therapeutics' FCF Margin skyrocketed by 11,435,348bps in 2017 and then tumbled by 12,091,355bps in 2018.
  • Over the past 5 years, Larimar Therapeutics' FCF Margin (Quarterly) stood at 8,934.02% in 2016, then skyrocketed by 11,435,348bps to 123,287.50% in 2017, then plummeted by 12,091,355bps to 2,373.95% in 2018, then slumped by 17,478bps to 2,199.17% in 2019, then surged by 48,666bps to 2,983.06% in 2020.
  • Its FCF Margin stands at 2,983.06% for Q1 2020, versus 2,199.17% for Q4 2019 and 1,366.90% for Q3 2019.